Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19345189 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Adorno M, et al. (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87-98 19345189
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S6-p - p53 (human)
Orthologous residues
p53 (human): S6‑p, p53 (mouse): S6‑p, p53 iso2 (mouse): S9‑p, p53 (rat): S6‑p, p53 (rabbit): S6‑p, p53 (monkey): S6‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  MDA-MB231 (breast cell), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease

S9-p - p53 (human)
Orthologous residues
p53 (human): S9‑p, p53 (mouse): S9‑p, p53 iso2 (mouse): S12‑p, p53 (rat): S9‑p, p53 (rabbit): S9‑p, p53 (monkey): S9‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  MDA-MB231 (breast cell), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 decrease

S423-p - Smad3 (human)
Orthologous residues
Smad3 (human): S423‑p, Smad3 (mouse): S423‑p, Smad3 (rat): S423‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  MDA-MB231 (breast cell), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase p53 wild-type
TGF-beta increase p53 -/-
TGF-beta increase p53 R175H mutant

S425-p - Smad3 (human)
Orthologous residues
Smad3 (human): S425‑p, Smad3 (mouse): S425‑p, Smad3 (rat): S425‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  MDA-MB231 (breast cell), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase p53 wild-type
TGF-beta increase p53 -/-
TGF-beta increase p53 R175H mutant


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.